Bright Horizons Psychiatry "*" indicates required fields
About 70% of patients treated with Spravato® show a clinically meaningful response.
You'll take Spravato® twice a week for the first month and once a week for the second month.
Several major payers cover Spravato® treatment for depression.
Treatment-resistant depression (TRD): This is depression that hasn’t improved after trying at least two different antidepressant medications.
Spravato is a brand-name nasal spray medication containing esketamine, which is a refined form of ketamine.
People with TRD or severe major depressive disorder (MDD) who haven’t seen improvement with other treatments like antidepressants and therapy.
It affects brain cells and increases glutamate production, potentially improving mood in ways that traditional antidepressants don’t.
Esketamine works quickly to relieve symptoms of treatment-resistant depression when traditional antidepressants haven’t helped.
Backed by science and most major health insurances
and many more
Dr. Amir Etesam, MD, is a Johns Hopkins–trained, Board-Certified, psychiatrist and the founder of Bright Horizons Psychiatry in North Bethesda, Maryland. He is a distinguished member of Alpha Omega Alpha (AOA), the nation’s most respected medical honor society, recognizing excellence in scholarship and integrity in medicine.
Dr. Etesam’s clinical work is exclusively focused on patients with treatment-resistant major depressive disorder (TRD)—those who have not improved despite multiple trials of medication and therapy. His practice centers on advanced neuromodulation therapies, including Transcranial Magnetic Stimulation (TMS) and Intranasal Esketamine (Spravato®), provided in a private, state-of-the-art setting designed for comfort and healing.
He no longer accepts new patients for other psychiatric conditions such as anxiety, ADHD, bipolar disorder, or OCD.
For patients seeking care for other psychiatric conditions—such as anxiety, ADHD, bipolar disorder, and general mood or behavioral concerns—a highly trained team of psychiatric nurse practitioners works side-by-side with, and under the close supervision of Dr. Etesam. This collaborative model ensures that every patient receives the same standard of thoughtful, evidence-based care that defines Bright Horizons Psychiatry.
We’re not just healthcare providers. We’re real people who care deeply about your journey.
Led by Dr. Amir Etesam, our compassionate team includes nurse practitioners, mental health coordinators, and neuromodulation specialists—all focused on one thing: helping you heal.
Spravato is FDA-approved—and it’s changing lives for people with depression that hasn’t responded to other treatments.
Depression shouldn’t cost you everything. With insurance coverage and financial guidance, getting better is possible—and affordable.
Relief without the rollercoaster—Spravato offers powerful results with minimal side effects.
Spravato is a nasal spray medication containing esketamine, a refined form of ketamine. It’s FDA-approved to treat treatment-resistant depression (TRD) and severe major depressive disorder (MDD) with suicidal thoughts or actions.
Spravato may be an option if you haven’t seen improvement with other treatments like antidepressants and therapy.
Many insurance plans cover Spravato, but coverage can vary. Check with your insurance provider to confirm.
Common side effects include sedation, dissociation, nausea, and increased blood pressure.
Spravato is a safe and effective treatment for TRD and MDD when used as prescribed. However, it’s important to discuss potential risks and benefits with your doctor.
Spravato works differently than traditional antidepressants. It affects brain cells and increases glutamate production, potentially improving mood.
We are here to support you in the healing journey
"*" indicates required fields
